Major Depressive Disorder

The indication is the first for an antidepressant that selectively targets the serotonin 1A receptor—a regulator of mood and emotion.

New data from Sweden conflict with previous register-based research showing a “substantially” increased risk of mania among antidepressant-treated pediatric patients with unipolar depression.

Geoffrey Grammer, MD, offers guidance on navigating challenges such as elevated blood pressure and substance misuse and abuse regarding the use of esketamine.

Hanita Chhabra, MD, highlights safety and efficacy data of esketamine and shares practical implications for clinical practice.

William M. Sauve, MD, reviews the landscape of delivery mechanisms for ketamine agents, including intravenous, sublingual, and intramuscular.

Steve Harvey, MD, discusses the challenges of defining treatment resistant depression and provides and overview of treatment options.

New phase 2 data adds to the growing interest in the psychedelic treatment as a novel drug to treat MDD.

A prospective cohort analysis of pregnant women in Rotterdam shows a potential link between the popular drug class and emotional regulation development trajectories.

A study of 7 million-plus US adults shows telehealth visits for mental health conditions increased more than 10-fold during the COVID-19 pandemic.

A large systematic review assessing more than 60 drugs for bipolar depression shows only a handful were statistically signifcantly better than placebo per depressive symptom outcomes.

A proof-of-concept trial shows a program that addresses sleep pressure, circadian rhythm and hyperarousal in adolescents and young adults receiving mental health care is promising.

New cohort analysis shows residents entering medicine in 2020 were actually less likely to report symptoms of PTSD than their earlier peers.

The pioneer in social anxiety disorder discusses how the investigative nasal spay may alter the trajectory of patients' conditions.

The pioneer in social anxiety disorder discusses his involvement in a promising, fast-acting nasal spray showing promising outcomes in late-stage trials.

Instances of urgent IBD hospitalization, surgery, death or lack of response to steroid therapy are linked to symptoms of depression and anxiety.

Vistagen reported significant improvement of physician- and patient-reported anxiety among trial participants who underwent an anxiety-inducing public speaking exercise.

Clayton, a primary investigator in the drug's pivotal trials, discusses what the historic FDA approval means for managing PPD in women.

The approval marks the first indication for a postpartum depression drug—one that which has been touted for its rapid-acting effect and sustained benefits.

The results found those with sexual minority status were significantly more likely to attend prenatal care visits (20%) when compared with heterosexual women.

While tele-CBT did not lead to significant changes in short-term weight outcomes, it was effective in improving disordered eating behaviors and reducing psychological distress.

"Depression causes a large public health burden, and alcohol-related behavior is a potentially modifiable risk factor," Dr. Gemma Hammerton writes.

The baseline data for the initial 1000 participants recruited into the TX-YDSRN show 79.6% were diagnosed with a primary depressive disorder.

Investigators discuss the potential of psychedelic drugs as a new approach to treating mental illnesses, highlighting their therapeutic benefits and the need for further research to understand their effects, safety, and accessibility.

During the early pandemic period, video telehealth use increased among all veteran groups but differences were observed among American Indian/Alaska Native veterans.

The study suggests 1 in every 18 patients would need an MRI scan to detect such significant abnormalities.